clinical trial · NCT04136366
The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
Proliferative VitreoretinopathyADX-2191 (intravitreal methotrexate 0.8%)Standard surgical care procedure
brief summary
The GUARD Trial is a multi-center, randomized, controlled, adaptive Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of proliferative vitreoretinopathy.
started
Nov 15, 2019
primary completion
Jun 14, 2022
completion
Jun 14, 2022
last updated
Jul 9, 2025
official title
The GUARD Trial - Part 1: A Phase 3 Clinical Trial of Repeated Intravitreal Injections of ADX-2191 Versus Standard-of-Care for Prevention of Proliferative Vitreoretinopathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol